Acamprosate vs. Placebo in Bipolar Alcoholics (NCT00466661) | Clinical Trial Compass
CompletedPhase 4
Acamprosate vs. Placebo in Bipolar Alcoholics
United States33 participantsStarted 2007-04
Plain-language summary
To conduct a double-blind, randomized, placebo-controlled outpatient clinical trial of acamprosate in individuals with alcohol dependence and bipolar disorder who are also receiving mood stabilizing medication. The study will assess the safety and efficacy of acamprosate in alcohol-dependent bipolar patients as measured by its effects on alcohol use and mood symptoms relative to placebo.
The primary hypothesis to be tested is whether individuals with comorbid bipolar disorder and alcohol dependence who receive acamprosate plus mood stabilizer will have greater improvement in alcohol-related outcomes than those who receive mood stabilizer alone. A secondary hypothesis that will be explored is that alcohol-dependent bipolar individuals treated with acamprosate will have greater mood stability as compared to those treated with mood stabilizers alone.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adults ages 18-65
✓. Meet DSM-IV criteria for current (past 90 days) alcohol dependence
✓. Meet DSM-IV criteria for bipolar I or bipolar II disorder
✓. Currently on a mood stabilizing medication regimen, including the use of lithium, valproic acid, lamotrigine, carbamazepine, and/or antipsychotic agent FDA approved to treat bipolar disorder without any dosage adjustments in the past 30 days
✓. Must be able to remain free from alcohol for at least 3 days prior to medication initiation
✓. Subjects must be able to adequately provide informed consent and function at an intellectual level sufficient to allow the accurate completion of all assessment instruments
✓. Subjects must consent to random assignment and be willing to commit to medication treatment and follow-up assessments
Exclusion criteria
✕. Individuals with a primary psychiatric disorder other than bipolar disorder